Literature DB >> 1618751

Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides.

G Y Wu1, C H Wu.   

Abstract

A 21-mer oligodeoxynucleotide complementary to the polyadenylation signal for human hepatitis B virus (HBV) was complexed to a soluble DNA-carrier system that is targetable to hepatocytes via asialoglycoprotein receptors present on those cells. A cell line, HepG2 (2.2.15) that possesses asialoglycoprotein receptors and is permanently transfected with hepatitis B virus (ayw subtype) was exposed to complexed antisense DNA or controls. In the presence of complexed antisense DNA, the concentration of hepatitis B surface antigen in medium was 80% lower than controls after 24 h. Furthermore, during the next 6 days, there was no significant increase in surface antigen concentration in the presence of complexed antisense DNA. The inhibition could be effectively blocked by competition with an excess of free asialoglycoprotein. Total protein synthesis remained unchanged by exposure to complexed antisense sequences under identical conditions. In addition, HBV DNA in the medium and cell layers after 24-h exposure to complexed antisense sequences was 80% lower than in controls. The data indicate that antisense oligonucleotides complexed by a soluble DNA-carrier system can be targeted to cells via asialoglycoprotein receptors resulting in specific inhibition of hepatitis B viral gene expression and replication.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618751

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

Review 1.  Gene therapy of hepatic diseases: prospects for the new millennium.

Authors:  K Shetty; G Y Wu; C H Wu
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

2.  Current status of gene therapy in gastroenterology.

Authors:  Chang-Tai Xu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

3.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

Authors:  E A Biessen; H Vietsch; E T Rump; K Fluiter; J Kuiper; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

Review 4.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

Review 5.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

Review 6.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

7.  Gene therapy in gastroenterology.

Authors:  H S Pandha; N R Lemoine
Journal:  Gut       Date:  1996-02       Impact factor: 23.059

8.  Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells.

Authors:  S Li; H M Deshmukh; L Huang
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

9.  Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.

Authors:  T Laitala; H K Väänänen
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 10.  Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

Authors:  Kruti S Soni; Swapnil S Desale; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-11-10       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.